Anti-CD38 therapies in antibody mediated rejection
Tristan De Natte from Rouen for Ottawa #NephGR
youtu.be/83ym-Is7T4E?...
#Transplant #NephSky
Tristan De Natte from Rouen for Ottawa #NephGR
youtu.be/83ym-Is7T4E?...
#Transplant #NephSky
Anti-CD38 therapies in antibody-mediated rejection with Dr Tristan De Natte
YouTube video by Ottawa Nephrology
youtu.be
December 16, 2025 at 2:44 AM
Anti-CD38 therapies in antibody mediated rejection
Tristan De Natte from Rouen for Ottawa #NephGR
youtu.be/83ym-Is7T4E?...
#Transplant #NephSky
Tristan De Natte from Rouen for Ottawa #NephGR
youtu.be/83ym-Is7T4E?...
#Transplant #NephSky
December 15, 2025 at 5:39 AM
CD38 is a key mediator of NAD+ depletion in the brain of ZIKV-infected mice pubmed.ncbi.nlm.nih.gov/41362627/
December 11, 2025 at 5:54 AM
CD38 is a key mediator of NAD+ depletion in the brain of ZIKV-infected mice pubmed.ncbi.nlm.nih.gov/41362627/
Daratumumab : anti-CD38 with Fc effector function; teclistamab-cqyv: bispecific CD3-BCMA for those of us following along at home.
So a double whammy of MM cell killing.
So a double whammy of MM cell killing.
December 9, 2025 at 5:23 PM
Daratumumab : anti-CD38 with Fc effector function; teclistamab-cqyv: bispecific CD3-BCMA for those of us following along at home.
So a double whammy of MM cell killing.
So a double whammy of MM cell killing.
Dr. Rizman Romee presents on cytokine-induced memory-like (CIIML) NK cells in combination w/ BHV-1100, an antibody recruiting molecule (ARM) -> binds CD38 on MM and CD16 (via IgG) on NK cells -> enhances NK activation, CIML activity in animal model w/o NK fratricide. Ph 1 trial done (1/2) #ASH25
December 6, 2025 at 7:39 PM
Dr. Rizman Romee presents on cytokine-induced memory-like (CIIML) NK cells in combination w/ BHV-1100, an antibody recruiting molecule (ARM) -> binds CD38 on MM and CD16 (via IgG) on NK cells -> enhances NK activation, CIML activity in animal model w/o NK fratricide. Ph 1 trial done (1/2) #ASH25
This phase Ib/IIa study evaluating the safety, #Pharmacokinetics, #Pharmacodynamics, #Immunogenicity & preliminary efficacy of CM313, an anti-CD38 antibody, in SLE patients showed manageable safety & encouraging clinical efficacy. #medsky
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
December 2, 2025 at 11:00 PM
This phase Ib/IIa study evaluating the safety, #Pharmacokinetics, #Pharmacodynamics, #Immunogenicity & preliminary efficacy of CM313, an anti-CD38 antibody, in SLE patients showed manageable safety & encouraging clinical efficacy. #medsky
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib/IIa trial
www.nature.com/articles/s41...
www.nature.com/articles/s41...
November 26, 2025 at 5:19 PM
Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib/IIa trial
www.nature.com/articles/s41...
www.nature.com/articles/s41...
- #Apoptosis triggered by inflammatory cytokines & potential direct viral manipulation of T cell function, though 🦠 does not typically infect T cells directly.
- T cells in COVID patients show ⏫️ activation markers (CD38, CD69) ⏫️ expression of exhaustion markers PD-1 , CTLA-4 & in severe #COVID
- T cells in COVID patients show ⏫️ activation markers (CD38, CD69) ⏫️ expression of exhaustion markers PD-1 , CTLA-4 & in severe #COVID
November 23, 2025 at 8:29 AM
- #Apoptosis triggered by inflammatory cytokines & potential direct viral manipulation of T cell function, though 🦠 does not typically infect T cells directly.
- T cells in COVID patients show ⏫️ activation markers (CD38, CD69) ⏫️ expression of exhaustion markers PD-1 , CTLA-4 & in severe #COVID
- T cells in COVID patients show ⏫️ activation markers (CD38, CD69) ⏫️ expression of exhaustion markers PD-1 , CTLA-4 & in severe #COVID
Measuring affinity of plasmablast and plasma cell antibodies for the enzyme glucose-6-phosphate isomerase (GPI) in K/BxN mice provided ex vivo characterization of autoreactive IgG secreting cells during initial arthritis development
Arthritis & Rheumatology
doi.org/10.1002/art....
Arthritis & Rheumatology
doi.org/10.1002/art....
November 21, 2025 at 10:34 PM
Measuring affinity of plasmablast and plasma cell antibodies for the enzyme glucose-6-phosphate isomerase (GPI) in K/BxN mice provided ex vivo characterization of autoreactive IgG secreting cells during initial arthritis development
Arthritis & Rheumatology
doi.org/10.1002/art....
Arthritis & Rheumatology
doi.org/10.1002/art....
New insight into IgAN treatment landscape:
HCPLive spoke with Jurgen Floege, MD, at Kidney Week 2025 about the emerging CD38-targeted therapy, felzartamab for sustained immunologic and symptomatic responses in adults with high-risk IgA Nephropathy.
Learn more:
HCPLive spoke with Jurgen Floege, MD, at Kidney Week 2025 about the emerging CD38-targeted therapy, felzartamab for sustained immunologic and symptomatic responses in adults with high-risk IgA Nephropathy.
Learn more:
PREVAIL: Felzartamab’s Sustained Clinical Outcomes In IgAN, With Jurgen Floege, MD | HCPLive
ASN insights on felzartamab, a CD38-targeted therapy, show sustained immune modulation in IgA nephropathy, offering a novel treatment approach.
www.hcplive.com
November 21, 2025 at 11:00 AM
New insight into IgAN treatment landscape:
HCPLive spoke with Jurgen Floege, MD, at Kidney Week 2025 about the emerging CD38-targeted therapy, felzartamab for sustained immunologic and symptomatic responses in adults with high-risk IgA Nephropathy.
Learn more:
HCPLive spoke with Jurgen Floege, MD, at Kidney Week 2025 about the emerging CD38-targeted therapy, felzartamab for sustained immunologic and symptomatic responses in adults with high-risk IgA Nephropathy.
Learn more:
November 18, 2025 at 12:51 PM
GPR15 and CD38 define a subset of peripheral blood pathogenic effector Th2 cells associated with active eosinophilic esophagitis https://www.biorxiv.org/content/10.1101/2025.11.16.688265v1
November 17, 2025 at 5:17 PM
GPR15 and CD38 define a subset of peripheral blood pathogenic effector Th2 cells associated with active eosinophilic esophagitis https://www.biorxiv.org/content/10.1101/2025.11.16.688265v1
GPR15 and CD38 define a subset of peripheral blood pathogenic effector Th2 cells associated with active eosinophilic esophagitis https://www.biorxiv.org/content/10.1101/2025.11.16.688265v1
November 17, 2025 at 5:17 PM
GPR15 and CD38 define a subset of peripheral blood pathogenic effector Th2 cells associated with active eosinophilic esophagitis https://www.biorxiv.org/content/10.1101/2025.11.16.688265v1
ICYMI: New content online: CD38 as a driver of ageing
CD38 as a driver of ageing
Nature Reviews Endocrinology, Published online: 11 November 2025; doi:10.1038/s41574-025-01211-yCD38 as a driver of ageing
www.nature.com
November 13, 2025 at 8:52 PM
ICYMI: New content online: CD38 as a driver of ageing
Anti-CD38-Targeted Piperazine-Derived Lipid Nanoparticles Overcome Hepatic Clearance for mRNA Delivery to Multiple Myeloma Cells In Vivo https://www.biorxiv.org/content/10.1101/2025.11.12.687398v1
November 13, 2025 at 8:46 PM
Anti-CD38-Targeted Piperazine-Derived Lipid Nanoparticles Overcome Hepatic Clearance for mRNA Delivery to Multiple Myeloma Cells In Vivo https://www.biorxiv.org/content/10.1101/2025.11.12.687398v1
Anti-CD38-Targeted Piperazine-Derived Lipid Nanoparticles Overcome Hepatic Clearance for mRNA Delivery to Multiple Myeloma Cells In Vivo https://www.biorxiv.org/content/10.1101/2025.11.12.687398v1
November 13, 2025 at 8:46 PM
Anti-CD38-Targeted Piperazine-Derived Lipid Nanoparticles Overcome Hepatic Clearance for mRNA Delivery to Multiple Myeloma Cells In Vivo https://www.biorxiv.org/content/10.1101/2025.11.12.687398v1
Product Description
Daratumumab is a recombinant human monoclonal IgG1κ antibody that selectively binds to CD38, a transmembrane glycoprotein expressed on plasma cells, immune cells, and various hematopoietic lineages. #highpuritychemical
arizona-mall.com/product/dara...
Daratumumab is a recombinant human monoclonal IgG1κ antibody that selectively binds to CD38, a transmembrane glycoprotein expressed on plasma cells, immune cells, and various hematopoietic lineages. #highpuritychemical
arizona-mall.com/product/dara...
Daratumumab | CAS 945721-28-8 | Anti-CD38 Monoclonal Antibody for Immunological Research
Daratumumab (brand: Zhike®, produced by Janssen?Cilag/Cilag AG) is a human IgG1? monoclonal antibody targeting CD38, widely used in preclinical and immuno-oncology research on multiple myeloma and hematologic malignancies. Supplied as 100?mg in 5?mL vials. First approved in China in 2019 (S20190029).?? For laboratory research use only.?Please consult the staff for other purposes?
arizona-mall.com
November 12, 2025 at 9:00 AM
Product Description
Daratumumab is a recombinant human monoclonal IgG1κ antibody that selectively binds to CD38, a transmembrane glycoprotein expressed on plasma cells, immune cells, and various hematopoietic lineages. #highpuritychemical
arizona-mall.com/product/dara...
Daratumumab is a recombinant human monoclonal IgG1κ antibody that selectively binds to CD38, a transmembrane glycoprotein expressed on plasma cells, immune cells, and various hematopoietic lineages. #highpuritychemical
arizona-mall.com/product/dara...
New content online: CD38 as a driver of ageing
CD38 as a driver of ageing
Nature Reviews Endocrinology, Published online: 11 November 2025; doi:10.1038/s41574-025-01211-yCD38 as a driver of ageing
www.nature.com
November 11, 2025 at 8:51 PM
New content online: CD38 as a driver of ageing
How'd I miss this one? Phase 1b results for mezagitamab, an anti-CD38 monoclonal antibody. (All meds should come with a pronunciation guide.) #NephSky #KidneyWk #IgAN #IgANephropathy
Mezagitamab Stablized eGFR 18 Months After Treatment in IgAN
Phase 1b IgAN data: mezagitamab (TAK‑079) stabilized eGFR, reduced proteinuria and serum Gd-IgA1, no serious AEs through Week 96; Phase 3 trials enrolling.
www.takeda.com
November 11, 2025 at 3:25 PM
How'd I miss this one? Phase 1b results for mezagitamab, an anti-CD38 monoclonal antibody. (All meds should come with a pronunciation guide.) #NephSky #KidneyWk #IgAN #IgANephropathy
Datatumumab targets CD38 cells, which is expressed by amongst others plasma cells. Sirolimus prevents B cells from proliferating. Anti CD20 antibody targets B-cells and causes them to die
November 9, 2025 at 1:06 PM
Datatumumab targets CD38 cells, which is expressed by amongst others plasma cells. Sirolimus prevents B cells from proliferating. Anti CD20 antibody targets B-cells and causes them to die
Signing off #NiteFlirt for a while, but you can still buy my goodies at https://www.niteflirt.com/profile/SativaFoxx304?un=cd38#goodies.
November 7, 2025 at 4:48 PM
Signing off #NiteFlirt for a while, but you can still buy my goodies at https://www.niteflirt.com/profile/SativaFoxx304?un=cd38#goodies.
Widespread deployment of the human CD38 ADP-ribosyl cyclase fold in antibacterial and anti-eukaryotic polymorphic toxins - Journal of Biological Chemistry www.jbc.org/article/S002...
Widespread deployment of the human CD38 ADP-ribosyl cyclase fold in antibacterial and anti-eukaryotic polymorphic toxins
Bacterial polymorphic toxins are modular weapons that mediate intermicrobial competition
and host interactions by delivering diverse cytotoxic domains through specialized
secretion systems. Here, we i...
www.jbc.org
October 29, 2025 at 6:44 AM
Widespread deployment of the human CD38 ADP-ribosyl cyclase fold in antibacterial and anti-eukaryotic polymorphic toxins - Journal of Biological Chemistry www.jbc.org/article/S002...
Daratumumab Efficacy in Steroid-Resistant Nephrotic Syndrome Correlates with CD38+ B-Cell Depletion
www.kireports.org/article/S246...
www.kireports.org/article/S246...
Daratumumab Efficacy in Steroid-Resistant Nephrotic Syndrome Correlates with CD38+ B-Cell Depletion
The anti-CD38 monoclonal antibody daratumumab, alone or with anti-CD20 rituximab,
can induce remission in steroid-resistant nephrotic syndrome or multidrug-dependent
nephrotic syndrome.1 However, the ...
www.kireports.org
October 27, 2025 at 10:52 PM
Daratumumab Efficacy in Steroid-Resistant Nephrotic Syndrome Correlates with CD38+ B-Cell Depletion
www.kireports.org/article/S246...
www.kireports.org/article/S246...